Eli Lilly and Company

United States of America as Represented by the Administrator of Nasa

Chad Donald Paavola

Virender Kumar Sarin

Michael Patrick Akers

Ranajoy Majumdar

Chi Arch Nguyen

Nanette Elizabeth Schulte

Thomas Andrew Hardy

Jonathan D Trent

Michael Edward Christe

R Andrew McMillan

Hiromi Kagawa

Jun Zhang

Kenneth W Cullings

Julia C DeSimone

Suzanne L Chan

Yi-Fen Li

The invention is a composition of human insulin or insulin analog that includes specific concentrations of citrate, chloride, in some cases including the addition of sodium chloride, zinc and, optionally, magnesium chloride and/or surfactant, and that has faster pharmacokinetic and/or pharmacodynamic action than commercial formulations of existing insulin analog products.

Rapid-acting insulin compositions

The invention is a composition of insulin or insulin analog that has faster pharmacokinetic action than commercial formulations of rapid-onset insulin analog products.

The invention is a pharmaceutical composition of human insulin or insulin analog that includes citrate, treprostinil and stabilizing agents, that has faster pharmacokinetic and/or pharmacodynamic action than commercial formulations of existing insulin analog products and that is stable for commercial use.

A process for purifying laccase from an ectomycorrhizal fruiting body is disclosed. The process includes steps of homogenization, sonication, centrifugation, filtration, affinity chromatography, ion exchange chromatography, and gel filtration. Purified laccase can also be separated into isomers.

Methods for purifying enzymes for mycoremediation

The following application relates to nanotemplates, nanostructures, nanoarrays and nanodevices formed from wild-type and mutated chaperonin polypeptides, methods of producing such compositions, methods of using such compositions and particular chaperonin polypeptides that can be utilized in producing such compositions.

Ordered biological nanostructures formed from chaperonin polypeptides

The present invention provides chaperonin polypeptides which are modified to include N-terminal and C-terminal ends that are relocated from the central pore region to various different positions in the polypeptide which are located on the exterior of the folded modified chaperonin polypeptide. In the modified chaperonin polypeptide, the naturally-occurring N-terminal and C-terminal ends are joined together directly or with an intervening linker peptide sequence. The relocated N-terminal or C-terminal ends can be covalently joined to, or bound with another molecule such as a nucleic acid molecule, a lipid, a carbohydrate, a second polypeptide, or a nanoparticle. The modified chaperonin polypeptides can assemble into double-ringed chaperonin structures. Further, the chaperonin structures can organize into higher order structures such as nanofilaments or nanoarrays which can be used to produce nanodevices and nanocoatings.

Growing community of inventors

Carmel, IN, United States of America

Chad Donald Paavola